Should natalizumab be used despite JC virus positivity?-Commentary.
作者信息
Hedström Anna Karin
机构信息
Department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden.
出版信息
Mult Scler. 2025 Jul;31(8):920-921. doi: 10.1177/13524585251346378. Epub 2025 May 30.
Abstract
摘要
相似文献
1
Should natalizumab be used despite JC virus positivity?-Commentary.尽管存在JC病毒阳性，那他珠单抗是否仍应使用？-评论
Mult Scler. 2025 Jul;31(8):920-921. doi: 10.1177/13524585251346378. Epub 2025 May 30.
2
Should natalizumab be used despite JC virus positivity? Yes.即便存在JC病毒阳性，那妥珠单抗是否仍应使用？答案是肯定的。
Mult Scler. 2025 Jul;31(8):916-918. doi: 10.1177/13524585251346374. Epub 2025 Jun 14.
3
Should natalizumab be used despite JC virus positivity? No.即便存在JC病毒阳性，那妥珠单抗是否仍应使用？答案是否定的。
Mult Scler. 2025 Jul;31(8):918-920. doi: 10.1177/13524585251346382. Epub 2025 May 30.
4
Natalizumab for induction of remission in Crohn's disease.那他珠单抗用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2006 Jul 19(3):CD006097. doi: 10.1002/14651858.CD006097.
5
Natalizumab for induction of remission in Crohn's disease.那他珠单抗用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2007 Jan 24(1):CD006097. doi: 10.1002/14651858.CD006097.pub2.
6
Asymptomatic reactivation of JC virus in patients treated with natalizumab.接受那他珠单抗治疗的患者中JC病毒的无症状再激活
N Engl J Med. 2009 Sep 10;361(11):1067-74. doi: 10.1056/NEJMoa0904267.
7
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.难治性克罗恩病患者中抗JC病毒抗体的患病率及那他珠单抗治疗的效果
Clin Gastroenterol Hepatol. 2015 Nov;13(11):1919-25. doi: 10.1016/j.cgh.2015.05.022. Epub 2015 May 19.
8
Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.多发性硬化症患者接受那他珠单抗治疗后对 JC 病毒的免疫应答：一项横断面和纵向研究。
Lancet Neurol. 2010 Mar;9(3):264-72. doi: 10.1016/S1474-4422(10)70006-5. Epub 2010 Jan 29.
9
Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.JC 病毒血清阳性的多发性硬化症患者的安全性、焦虑和那他珠单抗的持续使用。
Mult Scler. 2014 Jan;20(1):108-11. doi: 10.1177/1352458513495582. Epub 2013 Jul 4.
10
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.纳武利尤单抗相关进行性多灶性白质脑病的风险。
N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829.
本文引用的文献
1
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.多发性硬化症患者使用延长间隔剂量可降低纳他珠单抗相关进行性多灶性脑白质病的风险。
Neurology. 2019 Oct 8;93(15):e1452-e1462. doi: 10.1212/WNL.0000000000008243. Epub 2019 Sep 12.
2
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.多发性硬化症患者使用那他珠单抗相关进行性多灶性白质脑病的风险：四项临床研究数据的回顾性分析。
Lancet Neurol. 2017 Nov;16(11):925-933. doi: 10.1016/S1474-4422(17)30282-X. Epub 2017 Sep 29.
3
Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort.那他珠单抗停药后复发风险：来自法国TYSEDMUS队列的结果。
Neurol Neuroimmunol Neuroinflamm. 2016 Oct 28;3(6):e297. doi: 10.1212/NXI.0000000000000297. eCollection 2016 Dec.
4
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.那他珠单抗治疗多发性硬化症：更新的患者选择和监测建议。
Lancet Neurol. 2011 Aug;10(8):745-58. doi: 10.1016/S1474-4422(11)70149-1.
5
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.那他珠单抗治疗复发型多发性硬化症的随机安慰剂对照试验。
N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397.
Zotero 插件